Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 0 | 0 | 0 | 115 | 0 |
| Gross Profit | N/A | N/A | N/A | 115 | N/A |
| Operating Expenses | 12,679 | 9,732 | 10,772 | 10,124 | 11,309 |
| Operating Income | -12,679 | -9,732 | -10,772 | -10,009 | -11,309 |
| Interest Expense | 43 | 64 | 70 | 71 | 78 |
| Other Income | 58,168 | -318 | 5,645 | -1,315 | 1,038 |
| Pre-tax Income | 45,446 | -10,114 | -5,197 | -11,395 | -10,349 |
| Net Income Continuous | 45,446 | -10,114 | -5,197 | -11,395 | -10,349 |
| Net Income | $45,446 | $-10,114 | $-5,197 | $-11,395 | $-10,349 |
| EPS Basic Total Ops | 0.50 | -1.09 | -0.56 | -1.23 | -1.12 |
| EPS Basic Continuous Ops | 4.26 | -1.09 | -0.56 | -1.23 | -1.12 |
| EPS Diluted Total Ops | -0.21 | -1.09 | -0.56 | -1.23 | -1.12 |
| EPS Diluted Continuous Ops | 0.58 | -1.09 | -0.56 | -1.23 | -1.12 |
| EPS Diluted Before Non-Recurring Items | -0.21 | -1.09 | -0.56 | -1.23 | -1.12 |
| EBITDA(a) | $-11,937 | $-8,966 | $-10,013 | $-9,243 | $-10,391 |